Impressive results in lung cancer with Eli Lilly’s Ret inhibitor set the stage for approval next year, but Blueprint is not far behind.
Positive data should pave the way for ripretinib’s approval in fourth-line GIST, but investors are already eyeing a bigger opportunity.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
The small-molecule oncology player zeroes in on its first commercial opportunity.
Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Vitrakvi and LOXO-195 with Bayer.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The relatively niche cancer setting provides an important battleground for the targeted kinase inhibitor specialists Blueprint Medicines and Loxo Oncology.
Takeda's drug leads the charge of small-molecule tyrosine kinase inhibitors, some of which are very much holding their own against the onslaught of immuno-oncology.